Development and validation of nomograms to predict overall survival and cancer specific survival of patients with primary fallopian tube carcinoma-Reference-Cited by-同舟云学术

Development and validation of nomograms to predict overall survival and cancer specific survival of patients with primary fallopian tube carcinoma

Published:2023-01-09 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Chen Ming¹,zeng Li¹,Meng Muzi²,Lowe Scott³,Liu Xiaozhu⁴,Hu Pengcheng⁵,Liu Mengnan⁶,Zeng Yuxue⁷,Liu Ling⁸,Mao Xiguang⁹,Yin Chengliang¹⁰,Sun Chenyu¹¹,Sun Xingyu⁹

Affiliation:

1. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu City, Sichuan Province, China

2. UK Program Site, American University of the Caribbean School of Medicine, Vernon Building Room 64, Sizer St, Preston PR1 1JQ, United Kingdom

3. College of Osteopathic Medicine, Kansas City University, 1750 Independence Ave, Kansas City, MO 64106; USA

4. Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

5. Department of Ophthalmology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

6. Faculty of Chinese Medicine and State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau SAR 999078, P.R. China

7. Department of Laboratory Medicine, The Traditional Chinese Medicine Hospital of Luzhou, Sichuan, 646000, China.

8. Department of Reproductive Medicine Center, the Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, China.

9. Department of Gynecology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.

10. Faculty of Medicine, Macau University of Science and Technology, Macau 999078, China.

11. AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore Drive, Chicago 60657, Illinois, USA.

Abstract

Abstract Background Primary fallopian tube carcinoma (PFTC) is a rare neoplasm. The purpose of this study is to identify which factors and markers contribute to affect the clinical prognosis of patients with PFTC, and to inform treatment and preventive strategies. Methods Patients were selected from those with confirmed PFTC registered in 2010 till 2015 from the Surveillance, Epidemiology and End Results (SEER) database. Independent prognostic factors were identified using univariate and multivariate Cox proportional hazard regression models. These factors were used to construct a nomogram model, a survival prognostication tool for3-and 5-year overall survival (OS) and tumor-specific survival (CSS) among patients with PFTC. Kaplan-Meier curves and log-rank tests were used to assess differences in survival time between groups. Results A total of 1241 patients were randomly assigned to the training group (n = 869) and the test group (n = 372). Kaplan-Meier survival analysis showed a similar 3-year/5-year OS and CSS in patients with PFTC (70.1%/55.4% and 71.7%/57.2%, respectively). In multivariate Cox regression analysis, age (22–56, 57–71 and 72–92), race (white, black and other), International Federation of Gynecology and Obstetrics (FIGO) staging (I, II, III, and IV) and laterality (lateral and bilateral) were independent prognostic factors for patients with PFTC. Finally, a nomogram consisting of age, race, FIGO stage, type of surgery and lymphadenectomy were constructed. The area under the time-dependent receiver operating characteristic (ROC) curve values of 3-/5-year OS were 0.730/0.750 in the training group and 0.726/0.803 in the test group. Conclusions Nomograms constructed using various clinical indicators could help identify patients with high-risk PFTC. We have identified prognostic factors associated with OS and CSS. These factors can be examined and included further in large clinical trials involving this rare carcinoma.

Publisher

Research Square Platform LLC

Reference34 articles.

1. Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 11, 902 – 12 (2006).

2. Extrauterine Pelvic Serous Carcinomas: Current Update on Pathology and Cross-sectional Imaging Findings;Katabathina VS;Radiographics.,2016

3. Rezvani M, Shaaban AM. Fallopian tube disease in the nonpregnant patient. Radiographics. 31, 527 – 48 (2011).

4. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US;Liao CI;Gynecol Oncol.,2018

5. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome;Medeiros F;Am J Surg Pathol,2006